Ibadan — A Nigerian-led research team has achieved a scientific breakthrough by producing the first-ever crystal structure of a key malaria parasite protein bound to an inhibitor, opening new pathways for malaria drug development.

The research, led by Dr. Olatomide Fadare and colleagues, successfully crystallized Plasmodium falciparum transketolase—an enzyme critical to the malaria parasite's metabolism—in complex with an inhibiting compound. The achievement, reported in the Protein Data Bank, represents years of painstaking laboratory work.

"Understanding the three-dimensional structure of this protein in its inhibited state gives us unprecedented insight into how we might design drugs to block it," explained Dr. Fadare. "This is foundational work that other researchers worldwide can now build upon."

Malaria remains one of Africa's deadliest diseases, killing over 600,000 people annually, predominantly children under five. Nigeria accounts for approximately 27% of global malaria cases and 31% of malaria deaths. Despite decades of intervention efforts, drug resistance and insufficient healthcare infrastructure keep malaria mortality stubbornly high.

The transketolase enzyme plays a crucial role in the parasite's pentose phosphate pathway, which generates molecules essential for parasite survival. Blocking this pathway could starve the parasite without harming human cells, making it an attractive drug target. Previous attempts to crystallize the protein in complex with inhibitors had failed, making this achievement particularly significant.

The research demonstrates African scientific capacity often overlooked in global narratives. Nigerian universities and research institutions, despite chronic underfunding and infrastructure challenges, continue producing world-class science. Dr. Fadare's team worked with limited resources compared to Western counterparts, yet achieved results that eluded better-funded laboratories.

said , a biochemist at the not involved in the research.